RACHEL TAYLOR: Open Payments
NPI 1700532744 · OPELOUSAS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,157 in 55 payments from 14 companies in 2025. Trend: 2023 $418 · 2024 $1,100 · 2025 $1,157
Food & beverage: $1,145Education: $12
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $379 |
| Alkermes, Inc. | 11 | $208 |
| Vanda Pharmaceuticals Inc. | 8 | $148 |
| ABBVIE INC. | 5 | $90 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| Teva Pharmaceuticals USA, Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $40 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
Products named: CAPLYTA, FANAPT, ARISTADA, VRAYLAR, LYBALVI, Auvelity, UZEDY, MOUNJARO.
Industry payments across LA — which companies pay providers there.
